Nektar Therapeutics Stock Price, News & Analysis

Nektar Therapeutics (Nasdaq: NKTR) has appointed Dr. Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer. Dr. Nuyten will oversee the company's clinical strategy, including clinical operations and medical affairs. He brings extensive experience from previous leadership roles at Bristol Myers Squibb and Pfizer, where he led significant oncology programs. Brian Kotzin, M.D., who served as interim CMO, will continue as Senior Vice President of Clinical Development and Head of Immunology. The appointment aligns with Nektar’s growth in developing innovative therapies.

Nektar Therapeutics (Nasdaq: NKTR) will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 2:10 p.m. ET. This event allows investors to gain insights into Nektar's strategic direction and pipeline developments. The presentation can be accessed via a webcast on Nektar's Investor Events page and will remain available for replay until July 9, 2021. Nektar is a biopharmaceutical company focused on oncology, immunology, and virology, headquartered in San Francisco.

Nektar Therapeutics (NKTR) published preclinical data on NKTR-358 in the Journal of Translational Autoimmunity, showcasing its ability to selectively stimulate T regulatory (Treg) cell function for treating autoimmune disorders. The data indicated that NKTR-358 promotes sustained Treg expansion while minimizing T effector cell proliferation. Key findings included enhanced pharmacokinetics and efficacy in murine models of systemic lupus erythematosus (SLE). Continued clinical development is supported by ongoing Phase 2 studies conducted by Eli Lilly in various autoimmune conditions.

Nektar Therapeutics (NKTR) published pivotal preclinical data on NKTR-255, an IL-15 receptor agonist, in the Journal for ImmunoTherapy of Cancer. The data indicate NKTR-255 shows enhanced pharmacologic properties and superior anti-tumor efficacy compared to existing IL-15 agonists. This positions NKTR-255 favorably in its ongoing clinical trials for treating hematologic malignancies and solid tumors. The drug retains receptor binding like rhIL-15 while exhibiting reduced clearance and a longer half-life, supporting its therapeutic potential in immuno-oncology.

Nektar Therapeutics (NKTR) reported its financial results for Q1 2021, revealing a revenue decline to $23.6 million from $50.6 million in Q1 2020, primarily due to a previous milestone payment. Operating costs decreased to $133.0 million, significantly lower than $184.2 million the year prior, aided by reduced R&D expenses of $95.6 million. The net loss narrowed to $123.0 million or $0.68 per share, compared to $138.7 million or $0.78 per share in Q1 2020. The company continues advancing its clinical pipeline with ongoing studies for its lead drug, bempegaldesleukin, across various cancer indications.

Nektar Therapeutics (Nasdaq: NKTR) will disclose its financial results for Q1 2021 on May 6, 2021, post-market close. CEO Howard Robin will lead a conference call at 5:00 p.m. ET to discuss these results. Investors can access the press release and live audio webcast on the Nektar website. The conference call can be reached by dialing (877) 881-2183 for U.S. callers or (970) 315-0453 for international attendees, with a Conference ID of 9233368. The recorded webcast will be available for replay until May 27, 2021.

Nektar Therapeutics (NKTR) reported its financial results for Q4 and the full year 2020. Q4 revenue decreased to $23.5 million from $33.9 million in 2019, while annual revenue rose to $152.9 million, driven by $50 million in milestones from Bristol-Myers Squibb. Operating expenses totaled $134.2 million for Q4 and $578 million for the year, reflecting higher R&D costs despite a decrease in R&D expenses from 2019. The company reported a net loss of $117.2 million for Q4, and $444.4 million for the year. Nektar continues to advance its pipeline, notably with ongoing studies of bempegaldesleukin.

Nektar Therapeutics (NKTR) will announce its fourth quarter and annual financial results for 2020 on February 25, 2021, after U.S. markets close. A conference call hosted by President and CEO Howard Robin will begin at 5:00 p.m. ET. Investors can access the call via the company's website. Nektar specializes in biopharmaceuticals with a diverse portfolio in oncology, immunology, and virology. The results are highly anticipated as they will provide insights into the company's performance and future outlook.

Nektar Therapeutics (NASDAQ: NKTR) announced a collaboration with Merck for a Phase 2/3 clinical trial of bempegaldesleukin (BEMPEG) combined with KEYTRUDA® (pembrolizumab) in treating metastatic or unresectable recurrent squamous cell carcinoma of the head and neck. The study aims to enroll 500 patients and will assess overall response rate (ORR) and overall survival (OS). An interim analysis will be performed after 200 patients have been followed for at least four months. If successful, the trial will proceed to the Phase 3 stage.